Oxford BioDynamics (LON:OBD) Reaches New 1-Year Low – Here’s Why

Oxford BioDynamics Plc (LON:OBD)’s share price hit a new 52-week low on Monday . The company traded as low as GBX 0.82 ($0.01) and last traded at GBX 0.86 ($0.01), with a volume of 1545239 shares trading hands. The stock had previously closed at GBX 1 ($0.01).

Oxford BioDynamics Trading Down 13.6 %

The company has a fifty day moving average of GBX 1.25 and a 200-day moving average of GBX 3.87. The company has a market capitalization of £2.69 million, a price-to-earnings ratio of -14.37 and a beta of 0.42. The company has a current ratio of 0.68, a quick ratio of 2.80 and a debt-to-equity ratio of 370.22.

Insider Transactions at Oxford BioDynamics

In other Oxford BioDynamics news, insider David Holbrook purchased 49,653 shares of the firm’s stock in a transaction dated Monday, October 28th. The shares were purchased at an average cost of GBX 1 ($0.01) per share, with a total value of £496.53 ($606.19). Corporate insiders own 16.78% of the company’s stock.

About Oxford BioDynamics

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.